Corrected: Kentucky takes PBMs to court over 'outrageous' insulin prices

Paul Schloesser

Associate Editor

Kentucky is suing several pharmacy benefit managers, adding them to an existing suit against insulin makers and accusing them of violating multiple consumer rights laws regarding the price of insulin.

In a case brought forward in Kentucky’s Franklin Circuit Court on Wednesday, the state’s Attorney General Daniel Cameron added PBM giants OptumRx, Express Scripts and CVS Caremark as defendants in an ongoing case that includes insulin manufacturers. Kentucky previously sued Novo Nordisk, Eli Lilly and Sanofi in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Corrected: Kentucky takes PBMs to court over 'outrageous' insulin prices

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work

Pharma companies soften tone on full IRA impact

ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to full approval

Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma

Novartis makes a $1B radiopharma deal, buying Mariana Oncology

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cor­rect­ed: Ken­tucky takes PBMs to court over 'outra­geous' in­sulin prices

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Phar­ma com­pa­nies soft­en tone on full IRA im­pact

ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

Block­buster can­cer drug Calquence hits pri­ma­ry end­point in tri­al for first-line man­tle cell lym­phoma

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

Corrected: Kentucky takes PBMs to court over 'outrageous' insulin prices

Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work

Pharma companies soften tone on full IRA impact

ICER pushes back on FDA's potential conversion of Sarepta's gene therapy to full approval

Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma

Novartis makes a $1B radiopharma deal, buying Mariana Oncology

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations